238 results on '"Harrison, Stephen"'
Search Results
2. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease
3. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis
4. Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH
5. Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study.
6. Rupert Brooke (1887–1915)
7. Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers
8. FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond
9. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
10. Degree of Discordance Between FIB-4 and Transient Elastography: An Application of Current Guidelines on General Population Cohort
11. A communication hub for phosphoregulation of kinetochore-microtubule attachment
12. Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH
13. NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials
14. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
15. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis
16. Liver biopsy evaluation in MASH drug development: Think thrice, act wise
17. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
18. A multisociety Delphi consensus statement on new fatty liver disease nomenclature
19. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study
20. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
21. Performance Assessment of a Thermoelectric Heat Pump Heat Recovery Ventilator
22. OS-087 Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease
23. SAT-450 Exploring racial, ethnic, and demographics representativeness in MASH clinical trials: combined data from multiple therapeutic trials including more than 10, 000 patients
24. LBO-002 Efruxifermin significantly reduced liver fibrosis in MASH patients with F2-F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study)
25. SAT-203 Pegozafermin added to background GLP-1 therapy in patients with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: ENLIVEN 48-week extension data
26. WED-219 Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model
27. GS-004 Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography-a multicenter cohort study of 10, 920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
28. THU-242 Comparison ofmachine learning model (MASML), VCTE, and FIB-4 scores for predicting the presence of MASLD in a large cohort of patients in the U.S. using the NHANES database
29. SAT-263 Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH/MASH serial liver biopsy study
30. LBP-014 Enhancing prediction of moderate fibrosis in MASLD patients for Resmetirom treatment via machine learning
31. THU-233 External validation of machine learning model (MASML) adjusted for prevalence for determining the histologic severity of MASLD in a large cohort of patients with biopsy-proven disease
32. SAT-208 Sex hormone binding globulin as an effective predictor of treatment response toTERN-501, a potent, highly selective thyroid hormone receptor β agonist: post-hoc analyses from a 12-week phase 2a trial
33. OS-054 Validation of the Baveno VII ‘rule of 5’ in a real-life multicentre cohort of patients with metabolic dysfunction associated steatotic liver disease
34. TOP-265 Non-invasive predictive markers of resmetirom biopsy response
35. SAT-220-YI Efruxifermin treatment improved collagen biomarkers consistent with remodelling of the extracellular matrix in patients with F2-F3 fibrosis due to MASH
36. WED-202 The 2023 AASLD practice guidance for MASLD does not adequately risk stratify MASLD patients in the context of therapeutic trials
37. WED-223 Clinical and biological predictors of liver fat content ≥8% as assessed by MRI-PDFF: combined data from multiple therapeutic trials including more than 10, 000 patients
38. SAT-214 Using machine learning models to predict baseline fibrosis stage in patients from phase 3 resmetirom trials (MAESTRO-NAFLD and MAESTRO-NASH)
39. FRI-208 qBallooning: AI-based ballooned hepatocyte detection and quantification by second harmonic generation/two photon excitation microscopy
40. TOP-289 Artificial intelligence-based measurement of non-alcoholic steatohepatitis is an accurate tool for clinical trial enrollment and end point assessment
41. FRI-199 Insulin resistance as an independent predictor of metabolic dysfunction-associated steatohepatitis (MASH) severity: combined data from multiple therapeutic trials including more than, 10 000 patients
42. SAT-227 Evaluation of efficacy of Berberine Ursodeoxycholate (HTD1801) compared to ongoing use of GLP-1 receptor agonists in patients with MASH and T2DM
43. GS-011 Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week international, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis
44. TOP-253 Clinical, biological and imaging predictors of at-risk MASH: combined data from multiple therapeutic trials including more than 10, 000 patients
45. TOP-300 Clinical, biological and imaging predictors of advanced fibrosis (F3-F4): combined data frommultiple therapeutic trials including more than 10, 000 patients
46. OS-124 Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH
47. SAT-243 Time course of onset, incidence and prevalence of gastrointestinal adverse events with HTD1801 (Berberine Ursodeoxycholate) in patients with MASH and T2DM
48. FRI-249 Association between uric acid concentration and MASH: combined data from multiple therapeutic trials including more than 10, 000 patients
49. WED-296 PLIN2 is a specific marker for liver related disease
50. WED-213 Assessment of fibrosis change rates in placebo arm of metabolic dysfunction-associated steatohepatitis drug trials based on pathologist readouts and qFibrosis continuous values
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.